• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Amgen - Articles and news items

ESC launches new concept for driving innovation in cardiovascular research with exclusive support from Boehringer Ingelheim

New data adds to understanding of Repatha® (evolocumab) in multiple patient populations

Industry news / 23 August 2016 / Amgen

Amgen will present data evaluating Repatha® (evolocumab) at the upcoming European Society of Cardiology (ESC) Congress 2016 in Rome…

osteoporosis fracture

UCB and Amgen submit FDA application for Osteoporosis drug

Industry news / 22 July 2016 / Niamh Louise Marriott, Digital Content Producer

UCB and Amgen today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for romosozumab, an investigational, monoclonal antibody for the treatment of osteoporosis in postmenopausal women at increased risk of fracture…

kyprolis

EC approves extended indication for Kyprolis in multiple myeloma

Industry news / 4 July 2016 / Victoria White, Digital Content Producer

The EC has approved a variation to the marketing authorisation for Amgen’s Kyprolis (carfilzomib) to include use in combination with dexamethasone alone…

nice

NICE recommends five drugs to treat four different conditions

Industry news / 22 June 2016 / Victoria White, Digital Content Producer

NICE has published final guidance recommending that five drugs to treat four different conditions should be routinely funded by the NHS…

amgen

Esteban Santos appointed Amgen’s vice president, Operations

Industry news / 20 June 2016 / Victoria White, Digital Content Producer

Santos will be responsible for Amgen’s Operations organisation, including manufacturing, process development, quality, engineering and global supply chain…

kyprolis

Amgen presents new data for Kyprolis in multiple myeloma at EHA

Industry news / 13 June 2016 / Victoria White, Digital Content Producer

A post-hoc analysis of the Phase III ASPIRE study highlighted the benefit of continued treatment with Kyprolis, lenalidomide and dexamethasone (KRd)…

blincyto

Blincyto improves overall survival in B-cell precursor acute lymphoblastic leukaemia

Industry news / 10 June 2016 / Victoria White, Digital Content Producer

Amgen’s Blincyto (blinatumomab) demonstrated an almost two-times increase in median overall survival compared to standard of care…

amg 334

AMG 334 significantly reduces monthly migraine days in study

Industry news / 9 June 2016 / Victoria White, Digital Content Producer

Novartis has announced positive first results from a Phase II investigating the efficacy and safety of AMG 334 (erenumab) in chronic migraine prevention…

Kyprolis

Amgen receives positive CHMP opinion to extend indication of Kyprolis

Industry news / 27 May 2016 / Victoria White, Digital Content Producer

The CHMP has adopted a positive opinion to extend the indication for Kyprolis to include treatment in combination with dexamethasone in multiple myeloma…

evolocumab

NICE recommends alirocumab and evolocumab in draft guidance

Industry news / 6 May 2016 / Victoria White, Digital Content Producer

Alirocumab and evolocumab are recommended for adults with primary hypercholesterolaemia or mixed dyslipidaemia…

itp

Amgen’s Nplate shows significant increase in durable platelet response in ITP

Industry news / 21 April 2016 / Victoria White, Digital Content Producer

A Phase III study shows that 52 percent of Nplate patients achieved a durable platelet response, compared with 10 percent of placebo-treated patients…

romosozumab

Positive top-line results from Phase III study of romosozumab in osteoporosis

Industry news / 21 March 2016 / Victoria White

The study demonstrated a statistically significant increase in bone mineral density at the lumbar spine in men with osteoporosis treated with romosozumab…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +